November 2010
SAMe for Depression?
The first placebo-controlled trial of SAMe as an adjunct to antidepressants in patients with treatment-resistant depression has yielded positive results.
IV Ketamine for Bipolar Depression
In a randomized, add-on trial, one infusion of IV ketamine improved depressive symptoms in patients with treatment-resistant bipolar depression.
Receptor-Binding Profiles of New Antipsychotics
The new antipsychotics paliperidone (Invega), iloperidone (Fanapt), and asenapine (Saphris) have different receptor-binding properties.
Sex Steroids for Schizophrenia?
In a double-blind trial, low-dose pregnenolone but not dehydroepiandrosterone (DHEA) improved outcomes in patients with schizophrenia when used to augment antipsychotic treatment.
In Brief
FDA Advisory Committee Votes Against Approval of Weight-Loss Drug Lorcaserin; Neonatal Levels of Vitamin D Associated with Increased Schizophrenia Risk; Warning Issued that Anticonvulsant Drug Lamotrigine (Lamictal) Can Cause Aseptic Meningitis
ADHD Symptoms, Food Additives, and Genetic Variations
Genetic variations may underlie differences in how artificial food dyes affect attention-deficit/hyperactivity disorder (ADHD) symptoms in children.
SAMe for Depression?
November 2010
S-adenosyl methionine (SAMe), a natural product that can be purchased over the counter, has been studied as a treatment for depression. Much of the research on SAMe has had methodological limitations, and early studies were hampered by difficulties synthesizing a stable oral form that had predictable…
To view the rest of this article, please:
For current
BTP subscribers
Purchase access
to all articles
Purchase this article
for $3 (USD)